BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jan 13, 2025
Deals

Lilly catches Relay in PI3Ka race via Scorpion acquisition

A spinout will house precision oncology assets from Scorpion
BioCentury | Dec 12, 2024
Data Byte

Candel leads biotech gainers amid wave of data readouts

Prostate cancer data lead to a nearly 70% stock bump; dermatitis data sink Q32 shares
BioCentury | Nov 9, 2024
Data Byte

FDA’s October approvals include the first CLDN18.2 mAb

Plus: Agency approves Pfizer’s hemophilia A and B mAb, and label expansions for five products
BioCentury | Oct 24, 2024
Product Development

Vaderis: A case study in navigating the orphan drug development maze

Company went from idea to clinical proof of concept for
BioCentury | Sep 13, 2024
Finance

Public Equity Report: Biotech quintet raises $1.3B+ via follow-ons

Ionis tops list of five biotechs raising at least $200M in public offerings, along with Centessa, Viridian, Relay and Xencor; plus PIPEs keep flowing
BioCentury | Sep 12, 2024
Product Development

Clinical Report: AstraZeneca, Daiichi turn to precision medicine after OS miss for Dato-DXd

Plus: Results from Relay, Centessa, Viridian, Amgen and more
BioCentury | Jul 18, 2024
Finance

Venture Report: Five biotechs raise nearly $800M in two-day flurry 

Plus: New capital for CytoReason, Truvian and Renalys
BioCentury | Jun 21, 2024
Finance

Venture Report: Syncona’s backs a pair of biotechs; Marea makes debut with $190M

Plus: Forbion’s new sustainability fund, and rounds for Elion, ashibio, NephroDI and Ability
BioCentury | May 31, 2024
Finance

Public Equity Report: Insmed, Merus raise combined $1B+ after readouts

Plus: PIPEs help Celcuity, Cargo advance clinical programs
BioCentury | May 17, 2024
Finance

Public Equity Report: Erasca reboots, Telix plans NASDAQ listing

Plus: OnKure goes public via reverse merger, Monte Rosa and Allogene each raise $100M+, and Incyte’s $2B buyback
Items per page:
1 - 10 of 870